Name	MC-VA
Antibody-Linker Relation	Cleavable
Structure
				2D MOL
Isosmiles	OC([C@H](C)NC([C@H](C(C)C)NC(CCCCCN1C(C=CC1=O)=O)=O)=O)=O

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	90.41%
In Vivo Model	NCI-H929 CDX 3 mpk (Day 25)
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	98.82%
In Vivo Model	NCI-H929 CDX 6 mpk (Day25)

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01669 nM
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Degradation Concentration (DC50)	0.06 nM
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Degradation Concentration (DC50)	13.06 nM
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	99.94%
In Vivo Model	NCI-H929 CDX 3 mpk (Day 25)
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	100%
In Vivo Model	NCI-H929 CDX 6 mpk (Day25)

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.00269 nM
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.00941 nM
In Vitro Model	Plasma cell myeloma, Multiple myeloma	MM.1S cells		CVCL_8792
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Degradation Concentration (DC50)	0.075 nM
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Degradation Concentration (DC50)	13.8 nM
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.0183 nM
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.0776 nM
In Vitro Model	Plasma cell myeloma, Multiple myeloma	MM.1S cells		CVCL_8792
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 50 nM
In Vitro Model	Normal	PBMC cells		CVCL_0140

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.0540 nM
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600

Ref 1	Rational engineering of degradation tail-driven CELMoD-antibody conjugates for precision malignancy therapy